A critical discussion of the role of neuroimaging in mild cognitive impairment*
Henrike Wolf,
Vesna Jelic,
Hermann-Josef Gertz,
Agneta Nordberg,
Per Julin,
Lars-Olof Wahlund,
Henrike Wolf
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorVesna Jelic
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorHermann-Josef Gertz
Department of Psychiatry, University of Leipzig, Germany
Search for more papers by this authorAgneta Nordberg
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorPer Julin
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorLars-Olof Wahlund
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorHenrike Wolf,
Vesna Jelic,
Hermann-Josef Gertz,
Agneta Nordberg,
Per Julin,
Lars-Olof Wahlund,
Henrike Wolf
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorVesna Jelic
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorHermann-Josef Gertz
Department of Psychiatry, University of Leipzig, Germany
Search for more papers by this authorAgneta Nordberg
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorPer Julin
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorLars-Olof Wahlund
Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden;
Search for more papers by this authorHenrike Wolf, Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge Sjukhus, B84, S-14186 Huddinge, Sweden
e-mail: [email protected]
*
Throughout this paper, the designation mild cognitive impairment (MCI) is used as a generic term for all cognitive changes observed in ageing that are insufficient to meet dementia criteria. When reference is made to one of the specific concepts named MCI (such as MCI according to Zaudig, MCI according to Petersen), this is made clear in the text.
Abstract
Objective – In this paper, the current neuroimaging literature is reviewed with regard to characteristic findings in mild cognitive impairment (MCI). Particular attention is drawn to the possible value of neuroimaging modalities in the prediction and early diagnosis of Alzheimer's disease (AD).
Methods – First, the potential contribution of neuroimaging to an early, preclinical diagnosis of degenerative disorders is discussed at the background of our knowledge about the pathogenesis of AD. Second, relevant neuroimaging studies focusing on MCI are explored and summarized. Neuroimaging studies were found through Medline search and by systematically checking through the bibliographies of relevant articles.
Results – Structural volumetric magnetic resonance imaging (MRI) and positron emission tomography (PET)/single photon emission tomography (SPECT) are currently the most commonly used neuroimaging modalities in studies focusing on MCI. There were considerable variations in demographical and clinical characteristics across studies. However, significant hippocampal and entorhinal cortex volume reductions were consistently found in subjects with MCI as compared with cognitively unimpaired controls. While hippocampal and entorhinal cortex atrophy in subjects with MCI are also well-established risk factors for the development of AD, these measures cannot be regarded as being of high predictive value in an individual case. Evidence for other typical neuroimaging changes in MCI is still scarce. In PET and SPECT studies, reduced blood flow and/or glucose metabolism in temporoparietal association areas, posterior cingulate and hippocampus were associated with a higher risk of progressive cognitive decline in MCI. In quantitative electroencephalogram (QEEG), low beta, high theta, low alpha and slowed mean frequency were associated with development of dementia.
Conclusions – Existing studies suggest that neuroimaging measures have the potential to become valuable tools in the early diagnosis of AD. To establish their value in routine use, larger studies, preferably with long prospective follow-up are needed.
References
- 1 Beringer K, Mallison R. Vorzeitige Versagenszustände. Allg Z Psychiat 1949; 124: 100–30.
- 2 Kral VA, Cahn C, Mueller H. Senescent memory impairment and its relation to the general health of the aging individual. J Am Geriatr Soc 1964; 12: 101–13.
- 3 Reisberg B, Ferris SH, De Leon MJ, Crook T. Global deterioration scale (GDS). Psychopharmacol Bull (US) 1988; 24: 661–663.
- 4 Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–572.
- 5 Roth M, Tym E, Mountjoy CQ et al. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986; 149: 698–709.
- 6 Jelic V , Winblad B. Treatment of mild cognitive impairment: rationale, present and future strategies. Acta Neurol Scand 2003; 107(Suppl: 179): 83–93.
- 7 Knopman DS, Dekosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–53.
- 8 Nagy Z, Jobst KA, Esiri MM et al. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia 1996; 7: 76–81.
- 9 Jack CR Jr, Dickson DW, Parisi JE et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58: 750–7.
- 10 De Carli CS, Atack JR, Ball MJ et al. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration 1992; 1: 113–21.
- 11 Braak H, Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239–59.
- 12 Nagy Z, Esiri MM, Jobst KA et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995; 6: 21–31.
- 13 Riley KP, Snowdon DA, Markesbery WR. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study. Ann Neurol 2002; 51: 559–66.
- 14 Gertz HJ, Xuereb J, Huppert FA et al. Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol (Berl) 1998; 95: 154–156.
- 15 Terry RD, Masliah E, Salmon DP et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572–580.
- 16 Bobinski M, Wegiel J, Tarnawski M et al. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 414–420.
- 17 Gomez-Isla T, Price JL, McKeel DWJ, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491–4500.
- 18 Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999; 283: 496–497.
- 19 Shoghi-Jadid K, Small GW, Agdeppa ED et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 24–35.
- 20 Katzman R, Terry R, Deteresa R et al. Clinical, pathological and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988; 23: 138–144.
- 21 Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999; 354 : 919–920.
- 22 Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain; 123(3): 484–498.
- 23 Palmer K, Fratiglioni L, Winblad B. What is mild cognitive impairment? Variations in definitions and evolution of nondemented persons with cognitive impairment. Acta Neurol Scand 2003; 107(Suppl. 179): 14–20.
- 24 Killiany RJ, Gomez-Isla T, Moss M et al. Use of structural magnetic resonance imaging to predict who will get alzheimer's disease. Ann Neurol 2000; 47: 430–439.
- 25 Killiany RJ, Hyman BT, Gomez-Isla T et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002; 58: 1188–1196.
- 26 Fischl B, Salat DH, Busa E et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341–355.
- 27 Wolf H, Grunwald M, Ecke GM et al. The prognosis of mild cognitive impairment in the elderly. J Neural Transm Suppl 1998; 54: 31–50.
- 28 Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriatr Psychiatry 1998; 15: 803–812.
- 29 Petersen RC, Smith GE, Ivnik RJ et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274–1278.
- 30 Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord 2001; 12: 379–386.
- 31 Visser PJ. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 1999; 246: 477–485.
- 32 Kogure D, Matsuda H, Ohnishi T et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000; 41: 1155–1162.
- 33 Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85–94.
- 34 Marquis S, Moore MM, Howieson DB et al. Independent predictors of cognitive decline in healthy elderly persons. Arch Neurol 2002; 59: 601–606.
- 35 Kaye JA, Swihart T, Howieson D et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997; 48: 1297–1304.
- 36 De Leon MJ, Convit A, Wolf OT et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). PNAS 2001; 98: 10966–10971.
- 37 De Santi S, De Leon MJ, Rusinek H et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001; 22: 529–539.
- 38 Parnetti L, Lowenthal DT, Presciutti O et al. 1H-MRS, MRI-based hippocampal volume try, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment and probable Alzheimer's disease [see comments]. J Am Geriatr Soc 1996; 44: 133–138.
- 39 Scheltens P, Launer LJ, Weinstein HC, Barkhof F, Jonker C. The value of MRI and SPECT in the early diagnosis of Alzheimer's disease. Neurology 1994; 44(Suppl: 2): A179.
- 40 Vannini P, Almkvist O, Jonsson T, Hagman G, Wahlund LO, Dierks T. Examination of visuospatial processing in patients with mild cognitive impairment and healthy elderly subjects. Neurobiol Aging 2002; 23(Suppl. 1):S474 (Abstract).
- 41 Goekoop R, Rombouts SA, Barkhof F, Scheltens P. Brain activation measured with fMRI in mild cognitive impairment. Neurobiol Aging 2002; 23(Suppl. 1):S365 (Abstract).
- 42 Jobst KA, Smith AD, Barker CS et al. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1992; 55: 190–194.
- 43 Jobst KA, Smith AD, Szatmari M et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992; 340 :1179–1183.
- 44 De Leon MJ, Golomb J, George AE et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. Am J Neuroradiol 1993; 14: 897–906.
- 45 Bottino CM, Castro CC, Gomes RL, Buchpiguel CA, Marchetti RL, Neto MR. Volumetric MRI measurements can differentiate Alzheimer's disease, mild cognitive impairment and normal aging. Int Psychogeriatr 2002; 14: 59–72.
- 46 Convit A, De Leon MJ, Tarshish C et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging 1997; 18: 131–138.
- 47 Dickerson BC, Goncharova I, Sullivan MP et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001; 22: 747–754.
- 48 Du AT, Schuff N, Amend D et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 71: 441–447.
- 49 Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 1993; 50: 949–954.
- 50 Laakso MP, Soininen H, Partanen K et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions. J Neural Transm Park Dis Dement Sect 1995; 9: 73–86.
- 51 Laakso MP, Partanen K, Lehtovirta M et al. MRI of amygdala fails to diagnose early Alzheimer's disease. Neuroreport 1995; 6: 2414–2418.
- 52 Soininen HS, Partanen K, Pitkänen A et al. Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory. Neurology 1994; 44: 1660–1668.
- 53 Förstl H, Hentschel F, Sattel H et al. Age-associated memory impairment and early Alzheimer's disease. Only time will tell the difference. Azneimittelforschung/Drug Res 1995; 45: 394–397.
- 54 Wolf H, Grunwald M, Kruggel F et al. Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly. Neurobiol Aging 2001; 22: 177–186.
- 55 Xu Y, Jack CR Jr, O'Brien PC et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000; 54: 1760–1767.
- 56 Juottonen K, Laakso MP, Partanen K, Soininen H. Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. Am J Neuroradiol 1999; 20: 139–144.
- 57 Krasuski JS, Alexander GE, Horwitz B et al. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry 1998; 43: 60–68.
- 58 Mizuno K, Wakai M, Takeda A, Sobue G. Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: an MRI volume tric and memory assessment study. J Neurol Sci 2000; 173: 18–24.
- 59 Chetelat G, Desgranges B et al. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 2002; 13: 1939–1943.
- 60 Baron JC, Chetelat G, Desgranges B et al.In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001; 14: 298–309.
- 61 Callen DJ, Black SE, Gao F, Caldwell CB, Szalai JP. Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology 2001; 57: 1669–1674.
- 62 Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358 :201–205.
- 63 Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease. unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002; 99: 4703–4707.
- 64 Foundas AL, Leonard CM, Mahoney SM, Agee OF, Heilman KM. Atrophy of the hippocampus, parietal cortex and insula in Alzheimer's disease: a volume tric magnetic resonance imaging study. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10: 81–89.
- 65 Rombouts SA, Barkhof F, Witter MP, Scheltens P. Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett 2000; 285: 231–233.
- 66 Van Der Flier WM, Van Den Heuvel DM, Weverling-Rijnsburger AW et al. Magnetization transfer imaging in normal aging, mild cognitive impairment and Alzheimer's disease. Ann Neurol 2002; 52: 62–67.
- 67 Van Der Flier WM, Van Den Heuvel DM, Weverling-Rijnsburger AW et al. Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology 2002; 59: 874–879.
- 68 Kabani NJ, Sled JG, Shuper A, Chertkow H. Regional magnetization transfer ratio changes in mild cognitive impairment. Magn Reson Med 2002; 47: 143–148.
- 69 Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet 1999; 353: 2125.
- 70 Mungas D, Reed BR, Jagust WJ et al. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology 2002; 59: 867–873.
- 71 Wolf H, Wahlund LO, Julin P et al. Is bigger better? Evidence for the cerebral reserve hypothesis of dementia in two large, independently examined samples. Neurobiol Aging 2002; 23(Suppl. 1):S462 (Abstract).
- 72 Sasaki M, Ehara S, Tamakawa Y et al. MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary report. Am J Neuroradiol 1995; 16: 2001–2007.
- 73 Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease and other types of dementia. Am J Neuroradiol 2002; 23: 27–32.
- 74 Jernigan TL, Salmon DP, Butters N, Hesselink JR. Cerebral structure on MRI, Part II: specific changes in Alzheimer's and Huntington's diseases. Biol Psychiatry 1991; 29: 68–81.
- 75 Barber R, McKeith I, Ballard C, O'Brien J. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease and vascular dementia. J Neurol Neurosurg Psychiatry 2002; 72: 406–407.
- 76 Weis S, Jellinger K, Wenger E. Morphometry of the corpus callosum in normal aging and Alzheimer's disease. J Neural Transm Suppl 1991; 33: 35–38.
- 77 Vermersch P, Scheltens P, Barkhof F, Steinling M, Leys D. Evidence for atrophy of the corpus callosum in Alzheimer's disease. Eur Neurol 1994; 34: 83–86.
- 78 Hensel A, Wolf H, Kruggel F et al. Morphometry of the corpus callosum in patients with questionable and mild dementia. J Neurol Neurosurg Psychiatry 2002; 73: 59–61.
- 79 Janowsky JS, Kaye JA, Carper RA. Atrophy of the corpus callosum in Alzheimer's disease versus healthy aging. J Am Geriatr Soc 1996; 44: 798–803.
- 80 Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451.
- 81 Decarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung and Blood Institute Twin Study. Arch Neurol 2001; 58: 643–647.
- 82 Breteler MM, Van Swieten JC, Bots ML et al. Cerebral white matter lesions, vascular risk factors and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994; 44: 1246–1252.
- 83 Hickie I, Scott E, Wilhelm K, Brodaty H. Subcortical hyperintensities on magnetic resonance imaging in patients with severe depression – a longitudinal evaluation. Biol Psychiatry 1997; 42: 367–374.
- 84 Grady CL, Haxby JV, Horwitz B et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol 1988; 10: 576–596.
- 85 Haxby JV, Grady CL, Koss E et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 1990; 47: 753–760.
- 86 Kennedy AM, Rossor MN, Frackowiak RS. Positron emission tomography in familial Alzheimer disease. Alzheimer Dis Assoc Disord 1995; 9: 17–20.
- 87 Nordberg A, Viitanen M et al. Longitudinal positron emission tomographic stidies in families with chromosome 14 and 21 encoded Alzheimer's disease. In: K Iqbal, JA Mortimer, B Winblad, HM Wiesniewski, eds. Research advances in Alzheimer's disease and related disorders. Chichester: Wiley, 1995.
- 88 Perani D, Grassi F, Sorbi S et al. PET study in subjects from two Italian FAD families with APP717 Val to Ileu mutation. Eur J Neurol 1997; 4: 214–220.
- 89 Julin P, Almkvist O, Basun H et al. Brain volumes and regional cerebral blood flow in carriers of the Swedish Alzheimer amyloid protein mutation. Alzheimer Dis Assoc Disord 1998; 12: 49–53.
- 90 Wahlund LO, Basun H, Almkvist O et al. A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. Dement Geriatr Cogn Disord 1999; 10: 526–533.
- 91 Johnson KA, Lopera F, Jones K et al. Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 2001; 56: 1545–1551.
- 92 Nybäck H, Nyman H, Blomqvist G. Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy sunjects. J Neurol Neurosurg Psychiatry 1991; 54: 672–678.
- 93 Matsuda H, Kitayama N, Ohnishi T et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J Nucl Med 2002; 43: 304–311.
- 94 Johnson KA, Jones K, Holman BL et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998; 50: 1563–1571.
- 95 Okamura N, Arai H, Maruyama M et al. Combined analysis of CSF tau levels and [123, I]iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry 2002; 159: 474–476.
- 96 Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment, BMC. Neurol 2002; 2: 9.
- 97 Ohnishi T, Hoshi H, Nagamachi S et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. J Nucl Med 1995; 36: 1163–1169.
- 98 Julin P, Lindqvist J, Svensson L, Slomka P, Wahlund LO. MRI-guided SPECT measurements of medial temporal lobe blood flow in Alzheimer's disease. J Nucl Med 1997; 38: 914–919.
- 99 Rodriguez G, Vitali P, Calvini P et al. Hippocampal perfusion in mild Alzheimer's disease. Psychiatry Res 2000; 100: 65–74.
- 100 Jelic V, Nordberg A. Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord; 14(Suppl. 1): S109–S113.
- 101 Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752–758.
- 102 Arnaiz E, Jelic V, Almkvist O et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001; 12: 851–855.
- 103 Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet 1994; 344: 895.
- 104 Hirono N, Mori E, Ishii K et al. Hypofunction in the posterior cingulate gyrus correlates with disorientation in time and place in Alzheimer's disease . J Neurol Neurosurg Psychiatry 1998; 64: 552–554.
- 105 Kitayama N, Matsuda H, Ohnishi T et al. Measurements of both hippocampal blood flow and hippocampal gray matter volume in the same individuals with Alzheimer's disease. Nucl Med Commun 2001; 22: 473–477.
- 106 Jelic V. Early diagnosis of Alzheimer's disease. Focus on quantitative EEG in relation to genetic, biochemical and neuroimaging markers. PhD Thesis. Stockholm: Karolinska Institutet.
- 107 Jelic V, Shigeta M, Julin P, Almkvist O, Winblad B, Wahlund LO. Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Dementia 1996; 7: 314–323.
- 108 Zappoli R, Versari A, Paganini M et al. Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. Ital J Neurol Sci 1995; 16: 341–376.
- 109 Grunwald M, Busse F, Hensel A et al. Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment and mild dementia. J Clin Neurophysiol 2001; 18: 178–184.
- 110 Huang C, Wahlund L, Dierks T, Julin P, Winblad B, Jelic V. Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol 2000; 111: 1961–1967.
- 111 Frodl T, Hampel H, Juckel G et al. Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's disease. Psychophysiology 2002; 39: 175–181.
- 112 Grunwald M, Busse F, Hensel A et al. Theta-power differences in patients with mild cognitive impairment under rest condition and during haptic tasks. Alzheimer Dis Assoc Disord 2002; 16: 40–48.
- 113 Olichney JM, Morris SK, Ochoa C et al. Abnormal verbal event related potentials in mild cognitive impairment and incipient Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 73: 377–384.
- 114 Elmståhl S, Rosén I. Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women. Dement Geriatr Cogn Disord 1997; 8: 180–187.
- 115 Jelic V, Johansson SE, Almkvist O et al. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging 2000; 21: 533–540.
- 116 Nagy Z, Hindley NJ, Braak H et al. Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by ‘stages’: a prospective study. Dement Geriatr Cogn Disord 1999; 10: 109–114.
- 117 Celsis P, Agniel A, Cardebat D, Demonet JF, Ousset PJ, Puel M. Age-related cognitive decline: A clinical entity? A longitudinal study of cerebral blood flow and memory performance. J Neurol Neurosurg Psychiatry 1997; 62: 601–608.
- 118 Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C. The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. Alzheimer Dis Assoc Disord 1997; 11: 63–70.
- 119 Nordberg A, Jelic V, Arnaiz E et al. Brain functional imaging in early and preclinical Alzheimer's disease. In: K Iqbal, SS Sisodia, B Winblad, eds. Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. Chichester: Wiley, 2001: 153–164.
- 120 McKelvey R, Bergman H, Stern J, Rush C, Zahirney G, Chertkow H. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci 1999; 26: 23–28.
- 121 Silverman DH, Small GW, Chang CH et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 286(17): 2120–2127.
- 122 Silverman DH, Gambhir SS, Huang HW et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits . J Nucl Med 2002; 43: 253–266.
- 123 Varma AR, Adams W, Lloyd JJ et al. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 2002; 105: 261–269.
- 124 Jack CR Jr, Petersen RC, Xu YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999 52:1397–1403.
- 125 Visser PJ, Verhey FRJ, Ponds RWHM, Jolles J. Characteristics of preclinical Alzheimer's disease. Int J Geriatr Psychiatry 2002; 17: 88–89.
- 126 Convit A, De Asis J, De Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging 2000; 21: 19–26.
- 127 Hojjatoleslami A, Kruggel F, Von Cramon DY. Segmentation of white matter lesions from volume tric MR-images. In: C Taylor, A Colchester, eds. Medical image computing and computer-assisted intervention, Vol. 1679. Heidelberg: Springer, 1999: 52–61.
- 128 Kovalev VA, Kruggel F, Gertz HJ, Von Cramon DY. Three-dimensional texture analysis of MRI brain datasets. IEEE Trans Med Imag 2001; 20: 424–433.
- 129 Frisoni GB, Galluzzi S, Bresciani L, Zanetti O, Geroldi C. Mild cognitive impairment with subcortical vascular features Clinical characteristics and outcome. J Neurol 2002; 249: 1423–1432.
- 130 Fox NC, Warrington EK, Freeborough PA et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain; 119: 2001–2007.
- 131 Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H. Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study. Biol Psychiatry 2000; 47: 557–561.
- 132 Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000; 57: 339–344.
- 133 Jack CR Jr, Petersen RC, Xu YC et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786–794.
- 134 Wahlund LO, Almkvist O, Basun H, Julin P. MRI in successful aging, a 5-year follow-up study from the eighth to ninth decade of life. Magn Reson Imaging 1996; 14: 601–608.
- 135 Wang D, Doddrell DM. MR image-based measurement of rates of change in volumes of brain structures. Part I: method and validation. Magn Reson Imaging 2002; 20: 27–40.
- 136 Yamaguchi S, Meguro K, Shimada M, Ishizaki J, Yamadori A, Sekita Y. Five-year retrospective changes in hippocampal atrophy and cognitive screening test performances in very mild Alzheimer's disease: the Tajiri Project. Neuroradiology 2002; 44: 43–48.
- 137 Laakso MP, Partanen K, Riekkinen P et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996; 46: 678–681.
- 138 Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001; 57: 1756–1763.
- 139 Frisoni GB, Laakso MP, Beltramello A et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology 1999; 52: 91–100.
- 140 Galton CJ, Gomez-Anson B, Antoun N et al. Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 2001; 70: 165–173.
- 141 Laakso MP, Frisoni GB, Kononen M et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: a morphometric MRI study. Biol Psychiatry 2000; 47: 1056–1063.
- 142 Fein G, Di SV, Tanabe J et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000; 55: 1626–1635.
- 143 Convit A, De Leon MJ, Tarshish C et al. Hippocampal volume losses in minimally impaired elderly. Lancet 1995; 345: 266.
- 144 Laakso MP, Soininen H, Partanen K et al. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity and analysis of the incorrectly classified subjects. Neurobiol Aging 1998; 19: 23–31.
- 145 Kantarci K, Jack CRJ, Xu YC et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000; 55: 210–217.
- 146 Catani M, Cherubini A, Howard R et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001; 12: 2315–2317.
- 147 Kantarci K, Jack CRJ, Xu YC et al. Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 2001;219:101–107.
- 148 Jack CRJ, Petersen RC, Xu YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397–1403.
- 149 Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 2001; 7: 631–639.
- 150 Zaudig M. A new systematic method of measurement and diagnosis of mild cognitive impairment and dementia according to ICD-10 and DSM-III-R criteria. Int Psychogeriatr 1992; 4(Suppl. 2): 203–219.
- 151 Levy R. Aging-associated cognitive decline. Int Psychogeriatr 1994; 6: 63–68.
- 152 Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer disease. In: RD Terry, R Katzman, KL Bick, eds. Alzheimer disease. New York: Raven Press, 1994: 179–196.
- 153 Scheltens P, Fox N, Barkhof F, De Carli CS. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurology 2002; 1 :13–21.
- 154 Julin P. MRI, SPECT neuroimaging in mild cognitive impairment and Alzheimer's disease. PhD Thesis. Stockholm: Karolinska Institutet, 1997.
- 155 Minoshima S, Frey KA, Koeppe RA. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of flourine-18-FDG PET. J Nucl Med 1995; 36: 1238–1248.
